2021
Ferroptosis: mechanisms and links with diseases
https://www.nature.com/articles/s41392-020-00428-9
그림 2: ferroptosis의 신호 전달 경로에 대한 도식적 설명.
표시된 경로는 지질 ROS 생성을 통해 ferroptosis 감도를 제어합니다. 포스파티딜에탄올아민(PE); 인지질(PL-H); 인지질 알콕실 라디칼(PL-O·); 인지질 퍼옥실 라디칼(PL-OO·); 인지질 하이드로퍼옥사이드(PL-OOH); 트랜스페린(TF). 그림에 사용된 기호에는 생체 분자의 이름이 표시되어 있습니다.
그림 3: 페로프토시스 방지 경로의 개요.
ferroptosis, GSH 의존성 GPx4 경로 및 NADPH 의존성 FSP1 경로에서 확인된 두 가지 방어 메커니즘에 대한 도식적 설명. 글루타민(Gln); 글루타메이트(Glu); 시스테인(Cys); 글리신(Gly); 글루타티온-이황화물 환원효소(GSR); 자극 단백질 1 및 3(SP1/3); 핵인자 Y(NF-Y); cAMP-반응 요소 조절제-타우(CREM-타우); 초기 성장 반응 단백질 1(EGR1); 핵인자 κB(NF-κB); 스테롤 조절 결합 요소 1(SREBP1).
Table 1 Summary of ferroptosis inducers.
Compound/drug Target Mechanism Model
Erastin | System Xc− | Interfere cystine uptake and deplete GSH, increase LIP level | Cell line: HT-1080, SH-SY5Y | |
Piperazine erastin | System Xc− | Upregulate PTGS2, suppressed by vitamin E | BJeLR cells | |
Imidazole ketone erastin | System Xc− | Interfere cystine uptake and deplete GSH | Cell line: G-401, DLBCL xenograft model | |
Sulfasalazine | System Xc− | Interfere cystine uptake and deplete GSH | Nb2 lymphoma cells | |
Sorafenib | System Xc− | Blocks system Xc− and deplete GSH | HCC cells | |
Glutamate | System Xc− | Interfere cystine uptake and deplete GSH | HT-1080 cells | |
BSO (buthionine sulfoximine) | Glutamate-cysteine ligase | Mediate glutathione deficiency | Newborn rats | |
DPI2 | Interfere cystine uptake and deplete GSH | BJeLR cells | ||
Cyst(e)inase | Cysteine consumption | Deplete L-Cysteine via interfering transsulfuration pathway and/or increasing ROS production | PCa cells, FVB/N mice | |
BAY 87-2243 | Mitochondrial complex I | Suppress the activity of Mitochondrial complex I, increase ROS | Cell line: H460, G361 and SK-MEL-28 | |
Artesunate | Nrf2− antioxidant response element | Downregulate GSH level, upregulate lipid ROS and mediate ferritinophagy | Cell line: HNC, LX-2; ICR mice, | |
(1S,3R)-RSL3 | GPX4 | Inhibit the activity of GPX4 via binding selenocysteines at active-site | Cell line: BJeLR, HT-1080 | |
ML162, ML210, DPI 7, DPI 10, DPI 12, DPI 13, DPI 17, DPI 18, DPI 19 | GPX4 | Inhibit the activity of GPX4 | BJeLR cells | |
Altretamine | GPX4 | Inhibit the activity of GPX4 | U-2932 cells | |
Withaferin A | GPX4 and KEAP1 inactivation | Stimulate Nrf2 via binding KEAP1, inhibit GPX4 | IMR-32 and SK-N-SH cells | |
FIN56 | GPX4 and squalene synthase | Increase degradation of GPX4, suppress CoQ10 via targeting and stimulating SQS | Cell line: BJeLR, HT-1080, PACN1, MEFs | |
Statins (fluvastatin, lovastatin, simvastatin) | HMGCR | Inhibit HMGCR and suppress GPX4 biosynthesis | Cell line: HT-1080, HCC4006 | |
Hemoglobin | Release iron and produce lethal ROS | Cell line: OHSCs | ||
Hemin | Cause high level of HMOX1 and increase intracellular iron | Cell line: IMR-32, HT22, primary cortical neurons; Male Swiss albino mice | ||
FeCl2, (NH4)2Fe(SO4)2 | Release iron and produce lethal ROS | Cell line: IMR-32, OHSCs | ||
Non-thermal plasma | Ferritin | Break ferritin and induce reduction from Fe(III) to Fe(II) | Cell line: IMR-90-SV, SAS, Ca9-22 | |
Salinomycin, ironomycin | DMT1, ferritin, GPX4 | Decrease expression of GPX4 and ferritin, and inhibit DMT1 by interrupting lysosomal iron translocation | Cell line: BCSCs, CSC | |
Siramesine + lapatinib | Iron transport | Increase transferrin and decrease ferroportin | Cell line: MDA MB 231, MCF-7, ZR-75, SKBr3, A549, U87 | |
FINO2 (1,2-dioxolane) | Lipid | Inactivate GPX4 and lead to Fe(III) oxidation | Cell line: IGROV-1, NCI-H322 M, NCI60, BJ-hTERT | |
BAY 11-7085 | IκBα | Increase HO-1 related to redox regulation | Cell line: MCF-7, MDA-MB-231, MDA-MB-468, SKBR3 | |
Trigonelline,brusatol | NRF2 | Inhibit Nrf2 | Cell line: HNC, HNSCC | |
Artemisinin derivatives | Induce ROS and mediate oxidative stress | CCRF-CEM cells | ||
CIL41, CIL56, CIL69, CIL70, CIL75, CIL79 | Induce ROS(CIL56 mediate ferroptosis at low concentration while necrotic, non-suppressible phenotype at high) | Cell line:BJ cells, HT-1080 |
Table 2 Summary of ferroptosis inhibitors.
Compound/drug Target Mechanism Model
Vitamin E, α-toc, trolox, tocotrienols | LOX | Restrain LOX PUFA oxygenation | Cell line: PBMCs, Pfal1; Gpx4 KO C57BL/6J mice | |
Deuterated polyunsaturated fatty acid | Lipid peroxidation | Inhibit lipid peroxidation | APP/PS1 mice | |
Butylated hydroxytoluene, butylated hydroxyanisole | Lipid peroxidation | Inhibit lipid peroxidation | C57BL/6J mice | |
Ferrostatins, liproxstatins | Lipid peroxidation | Inhibit lipid peroxidation | Cell line: HEK-29, HT22, HT-1080 | |
CoQ10, idebenone | Lipid peroxidation | Target lipid peroxyl radicals | Cell line: HT1080, Pfa1, NCI-H460, NCI-H2291, NCI-H1703 and NCI-H446 | |
XJB-5-131, JP4-039 | Lipid peroxidation | Nitroxide-based mitochondrial lipid peroxidation mitigators | Cell line: HT-1080, BJeLR, and panc-1 cells | |
Baicalein | LOX | Inhibit 12/15-LOX | HT22 cells, TBI mice model | |
PD-146176 | LOX | Inhibit 15-LOX-1 | HEK-293 cells | |
AA-861 | LOX | Inhibit 5-LOX | HEK-293T cells; ALF rat | |
Zileuton | LOX | Inhibit 5-LOX | Cell line: LNCaP, K562, HT22 | |
Deferoxamine, ciclopirox, deferiprone | Iron | Reduce intracellular iron | HT-1080 | |
Glutamine deprivation, glutaminolysis inhibitor | Glutaminolysis | Maybe hinder mitochondrial TCA cycle | Cell line: HT-1080, MEFs | |
Cycloheximide | Protein synthesis | Inhibit xCT protein synthesis | Primary cortical neurons | |
β-mercaptoethanol | Reducing agent | Reduce Cys2 to Cys | OT-1 CD8þ T cell | |
Dopamine | Neurotransmitter | Increase the stability of GPX4 | Cell line: PANC1, HEY, MEF, HEK293 | |
Selenium | Selenoproteins | Enhance the number of selenoproteins | Cell line: MEFs, HT-1080 | |
Vildagliptin, alogliptin, linagliptin | Dipeptidyl-peptidase-4 | Reduce lipid peroxidation via inhibiting DPP4 | TP53-deficient CRC cells |
*************************************************************
'Ferroptosis' 카테고리의 다른 글
여러가지 세포 사멸 양식 및 주요 특징 (0) | 2021.11.07 |
---|---|
아폽토시스 와 페롭토시스의 상호관계 (0) | 2021.11.04 |
ferroptosis 후성 유전 적 조절자와 대사 변화 (0) | 2021.10.27 |
골육종의 ferroptosis 표적화 (0) | 2021.10.27 |
ferroptosis의 분자 메커니즘과 암 치료에서의 역할 (0) | 2021.10.26 |